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ARTICLE
The tRNAMet 4435A4G mutation in the mitochondrial
haplogroup G2a1 is responsible for maternally
inherited hypertension in a Chinese pedigree
Zhongqiu Lu1,2,6, Hong Chen2,6, Yanzi Meng2,6, Yan Wang2,6, Ling Xue2,6, Shaoce Zhi1, Qiaomeng Qiu1,
Li Yang3, Jun Qin Mo4 and Min-Xin Guan*,2,3,5
Mutations in mitochondrial DNA (mtDNA) have been associated with hypertension in several pedigrees with maternal
inheritance. However, the pathophysiology of maternally inherited hypertension remains poorly understood. We reported here
clinical, genetic evaluations and molecular analysis of mtDNA in a three-generation Han Chinese family with essential
hypertension. Eight of 17 matrilineal relatives exhibited a wide range of severity in essential hypertension, whereas none of the
offsprings of the affected father had hypertension. The age-at-onset of hypertension in the maternal kindred varied from 31 to
65 years, with an average of 52 years. Sequence analysis of mtDNA in this pedigree identiﬁed the known homoplasmic
4435A4G mutation, which is located at immediately 3¢ end to the anticodon, corresponding to the conventional position 37 of
tRNAMet, and 41 variants belonging to the Asian haplogroup G2a1. In contrast, the 4435A4G mutation occurred among mtDNA
haplogroups B5a, D, M7a2 and J. The adenine (A37) at this position of tRNAMet is extraordinarily conserved from bacteria to
human mitochondria. This modiﬁed A37 was shown to contribute to the high ﬁdelity of codon recognition, structural formation
and stabilization of functional tRNAs. However, 41 other mtDNA variants in this pedigree were the known polymorphisms. The
occurrence of the 4435A4G mutation in two genetically unrelated families affected by hypertension indicates that this
mutation is involved in hypertension. Our present investigations further supported our previous ﬁndings that the 4435A4G
mutation acted as an inherited risk factor for the development of hypertension. Our ﬁndings will be helpful for counseling
families of maternally inherited hypertension.
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INTRODUCTION
Hypertension is a major public health problem, affecting approxi-
mately 1 billion worldwide.1 The etiology of hypertension is not well
understood because of multi-factorial causes. Hypertension can be
caused by single-gene or multi-factorial conditions, resulting from
interactions between the environment and inherited risk factors.2 In
fact, human hypertension is a condition associated with endothelial
dysfunction and oxidative stress.3,4 Mitochondrial dysfunction has
been potentially implicated in both human and experimental hyper-
tension.5–7 Speciﬁcally, abnormal mitochondrial respiration results in
oxidative stress, uncoupling of the oxidative pathways for ATP synth-
esis and subsequent failure of cellular energetic processes.8 An inefﬁ-
cient metabolism caused by mitochondrial dysfunctions in skeletal
and vascular smooth muscles may lead to the elevation of systolic
blood pressure and, therefore, may be involved in the development of
hypertension.6,7,9,10 Maternal transmission of hypertension has been
implicated in some pedigrees, suggesting that the mutation(s) in
mitochondrial DNA (mtDNA) is one of the molecular bases for this
disorder.10–16 In particular, the 4295A4G and 4263A4Gm u t a t i o n s
in the tRNAIle gene, the 4401A4G mutation in the junction between
tRNAGln and tRNAMet genes, as well as the 4435A4G mutation in the
tRNAMet gene were associated with essential hypertension.14–17
With the aim of investigating a role of the mitochondrial genome in
the pathogenesis of hypertension in the Chinese population, a
systematic and extended mutational screening of mtDNA has been
initiated in several cohorts of essential hypertension Chinese sub-
jects.14–17 In the present study, we performed the clinical, genetic and
molecular characterization of another Han Chinese family with
suggestive maternally transmitted hypertension. Eight of 17 matri-
lineal relatives in this family exhibited variable severity and age-at-
onset in essential hypertension, while none of the offspring of affected
fathers had hypertension. Mutational analysis of the mitochondrial
genome in this Chinese family identiﬁed the known tRNAMet
4435A4G mutation, which is localized at the 3¢ end adjacent to the
anticodon (position 37) of tRNAMet.17–19 The adenine at this position
of tRNAMet is extraordinarily conserved from bacteria to human
mitochondria. The mitochondrial genome in this Chinese family
belonged to the Eastern–Asian haplogroup G2a1,20 while the
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www.nature.com/ejhg4435A4G mutation also occurs in the other mtDNA haplogroups:
B5a of a Chinese family with hypertension16 and D5 of a Chinese
family with LHON18 and a Japanese subject with diabetes.19 The
occurrence of the 4435A4G mutation in these genetically unrelated
subjects affected by the hypertension suggests that this mutation is
involved in the pathogenesis of hypertension.
SUBJECTS AND METHODS
Subjects
As a part of a genetic screening program for hypertension, a Han Chinese
family (Figure 1) was ascertained at the Hypertension Clinic of Wenzhou
Medical College. Informed consent, blood samples and clinical evaluations
were obtained from all participating family members, under the protocols
approved by the ethics committee of Wenzhou Medical College and the
Cincinnati Children’s Hospital Medical Center Institute Review Board. Mem-
bers of this family were interviewed and evaluated to identify both personal or
medical histories of hypertension and other clinical abnormalities.
Clinical evaluation
Members of this Chinese family underwent a physical examination and
laboratory assessment of cardiovascular disease risk factors. A physician
measured the systolic and diastolic blood pressures of subjects using a mercury
column sphygmomanometer and a standard protocol.1,21 The ﬁrst and the ﬁfth
Korotkoff sounds were taken as indicative of systolic and diastolic blood
pressure, respectively. The average of three such systolic and diastolic blood
pressure readings was taken as the examination blood pressure. Hypertension
was deﬁned according to the recommendation of the Joint National Committee
on Detection, Evaluation and Treatment of High Blood Pressure (JNC VI)1 and
the World Health Organization-International Society of Hypertension21 as a
systolic blood pressure of Z140mmHg and/or a diastolic blood pressure of
Z90mmHg.
These subjects then underwent a heart function evaluation by electrocardio-
graphy (ECG). Signals from the ﬁrst 10s of the conventional ECG recording
were analyzed automatically in software to quantify all major intervals, axes and
voltages, as well as STsegment levels. Initial candidate criteria used for deﬁning
these strictly conventional 12-lead ECGs were as follows: left ventricular
hypertrophy (LVH) according to traditional Sokolow–Lyon voltage criteria22
(SV1+RV5 or RV6Z3.5mV) or gender-speciﬁc Cornell voltage
(RaVL+SV3Z2.8mV in men or Z2.0mV in women) criteria.23
Two-dimensional guided M-mode recording was performed from the
parasternal window according to the guidelines of the American Society of
Echocardiography. The following parameters on the M-mode echocardiogram
were evaluated: left ventricular end diastolic diameter (LVDd, cm), interven-
tricular septal diastolic thickness (IVSTd, cm), and left ventricular posterior
wall diastolic thickness (LVPWTd, cm). Left ventricular mass (LVM) was
calculated according to Devereux’s adjusted formula: LVM¼0.8 1.04 
[(LVDd+LVPWTd+IVSTd)3 LVDd3]+0.6g.24 Left ventricular mass index
(LVMI) was deﬁned as LVM divided by body surface area (BSA) (LVM/BSA,
g/m2). BSA was calculated according to the formula BSA¼0.6 height
(m)+0.0128 weight (kg) 0.1529. LVMI 4125g/m2 in males or 4115g/m2
in females was diagnosed as LVH.
Mutational analysis of mitochondrial genome
Genomic DNA was isolated from whole blood cells of participants using
Puregene DNA Isolation Kits (Gentra Systems, Minneapolis, MN, USA). The
entire mitochondrial genome of the proband II-9 was PCR ampliﬁed in 24
overlapping fragments by using sets of the light-strand and heavy-strand
oligonucleotide primers, as described elsewhere.25 Each fragment was puriﬁed
and subsequently analyzed by direct sequencing in an ABI 3700 automated
DNA sequencer (Applied Biosystems, Inc., Foster City, CA, USA) using the Big
Dye Terminator Cycle sequencing reaction kit. The resultant sequence datawere
compared with the revised consensus Cambridge sequence (GenBank accession
number: NC_012920).26
For the quantiﬁcation of the 4435A4G mutation, the PCR segments
(700bp) were ampliﬁed using genomic DNA as template and oligodeoxynu-
cleotides corresponding to mtDNA at positions 3861–4560, and subsequently
digested with a restriction enzyme NlaIII. In fact, the 4435A4Gm u t a t i o n
creates a novel site for this enzyme.18 Equal amounts of various digested
samples were then analyzed by electrophoresis through 7% polyacrylamide gel.
The proportions of digested and undigested PCR products were determined by
the Image-Quant program after ethidium bromide staining to observe whether
the 4435A4G mutation is in homoplasmy in these subjects.
Phylogenetic analysis
A total of 17 vertebrate mtDNA sequences were used in the interspeciﬁc
analysis. These include Bos Taurus, Cebus albifrons, Gorilla gorilla,
Homo sapiens, Hylobates lar, Lemur catta, Macaca mulatta, Macaca sylvanus,
Mus musculus, Nycticebus coucang, Pan paniscus, Pan troglodytes, Pongo
pygmaeus, Pongo abelii, Papio hamadryas, Tarsius bancanus, and Xenopus laevis
(Genbank). The conservation index (CI) was calculated by comparing the
human nucleotide variants with those of other 16 vertebrates. The CI was then
deﬁned as the percentage of species from the list of 16 different vertebrates that
have the wild-type nucleotide at that position.
Haplogroup analyses
The entire mtDNA sequence of the Chinese proband carrying the 4435A4G
mutation was assigned to an Asian mitochondrial haplogroup by using the
nomenclature of mitochondrial haplogroups.20
RESULTS
Clinical presentation
The proband (II-9) began suffering from hypertension at the age of 54
years. As shown in Table 1, his blood pressure was 190/110mmHg by
then. He came to the Hypertension Clinic of Wenzhou Medical
College for further clinical evaluations at the age of 60 years. After
the administration of ACE inhibitor, calcium channel blocker (CCB)
and diuretic, his blood pressure was 132/80mmHg. As shown in
Table 2, laboratory assessment of cardiovascular disease risk factors
showed that he had a normal range of the index of liver metabolic
function, the blood routine and 24-h urinary sodium. The echocar-
diogram (ECG) showed that his interventricular septal and posterior
ventricular wall thickness (13mm) increased with normal atrial and
ventricular dimension. Physical examination showed that he did not
have other clinical abnormalities, including diabetes, visual and
hearing impairments, renal and neurological disorders. Therefore, he
exhibited a typical essential hypertension. The family is originated
from Zhejiang Province in Eastern China. All members of this family
were interviewed and/or evaluated to identify both personal and
medical histories of hypertension and other clinical abnormalities.
As shown in Figure 1 and Table 1, 8 of 17 matrilineal relatives had a
wide range of severity in hypertension (with blood pressure 4140/
90mmHg even with treatment for hypertension), whereas only 1 of 8
nonmaternal relatives suffered from hypertension. None of the off-
spring of affected fathers exhibited hypertension. As shown in Table 1,
the age at onset of hypertension in eight affected matrilineal relatives
of the maternal kindred varied from 31 to 65 years, with an average of
Figure 1 The Chinese pedigree with hypertension. Affected individuals are
indicated by ﬁlled symbols. Arrowhead denotes the proband.
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European Journal of Human Genetics52 years. However, other nine unaffected matrilineal relatives, who
were below 52 years, had a tendency to develop the hypertension.
There was no evidence that any member of this family had any other
cause to account for hypertension. We further examined the end organ
damage on the heart and kidney among nine matrilineal relatives and
married-in subject II-3 of this family. As shown in Table 1, four (II-4,
II-8, III-4 and III-5) matrilineal relatives exhibited myocardial ische-
mia on the ECG recorded, while subject III-8 suffered from segment
elevation. In addition, none of eight matrilineal relatives, except the
proband, exhibited an increased interventricular septal thickness.
Furthermore, the clearance of endogenous creatinine and level of
urea nitrogen were assessed in 9 matrilineal relatives and 10 control
subjects. As shown in Table 1, the rates of endogenous creatinine
clearance in nine subjects (II-3, II-4, II-6, II-8, II-9, III-1, III-4, III-5
and III-8) were below the standard levels, whereas the level of urea
nitrogen among seven of nine matrilineal relatives were above the
standard levels. These data implicated the presence of renal dysfunction
in these patients. However, none of the other clinical abnormalities were
observed in the maternal kindred.
mtDNA analysis
The suggestively maternal transmission of hypertension in this family
implied the mitochondrial involvement and led us to analyze the
mitochondrial genome of matrilineal relatives. For this purpose, the
DNA fragments spanning the entire mtDNA of the proband II-6 were
PCR ampliﬁed, and each fragment was puriﬁed and subsequently
analyzed by direct sequence. As shown in Table 3, comparison of the
resultant sequences with the revised Cambridge consensus sequence26
identiﬁed the known hypertension-associated 4435A4Gm u t a t i o ni n
the tRNAMet gene17 and other 41 known nucleoside changes, belong-
ing to the Eastern–Asian haplogroup G2a1.20 Of other mtDNA
variants of the proband II-9, there were 12 polymorphisms in the
D-loop region, 2 variants in the 12S rRNA gene, 1 variant in the 16S
rRNA gene, the 5601C4T mutation in the tRNAAla gene, the
12280A4Gm u t a t i o ni nt h et R N A Leu(CUN) gene, the 17 silent muta-
tions and 6 missense mutations in protein encoding genes (http://
www.mitomap.org or http://www.genpat.uu.se/mtDB).13,27 These
missense mutations were the 4833A4G( 1 2 2 T 4A) in the ND2
gene, the 8701A4G( 5 9 T 4A)and 8860A4G (112T4A) in A6
gene, the 10398A4G( 1 1 4 T 4A) in the ND3 gene, and the
14766C4T( 7 T 4I) and 15326A4G( 1 9 4 T 4A) in the Cytb gene.
These variants in tRNAs, rRNAs and polypeptides were further
evaluated by phylogenetic analysis of these variants and sequences
from 16 vertebrates including mouse,28 bovine,29 and Xenopus laevis.30
The conservation index (CI) was calculated by comparing the human
nucleotide variants with 16 other vertebrates. CIs of these variants
including the tRNAAla 5601C4TandtR N A Leu(CUN) 12280A4G were
o70% CI, which was below the threshold level to be functionally
signiﬁcant in terms of mitochondrial physiology, as proposed by
Wallace.31 This suggests that these variants may not be functionally
signiﬁcant. Based on the nomenclature of mitochondrial hap-
logroups,20 we used the mtDNA sequence variations of the Chinese
proband to establish the haplogroup afﬁliation of his mtDNA. Here,
mtDNA of this pedigree belonged to the Eastern–Asian halpogroup G2a1.
The known 4435A4Gm u t a t i o ni nt h et R N A Met gene, as shown
in Figure 2, is located at immediately 3¢ end to the anticodon,
Table 1 Summary of clinical data for some members in a Chinese pedigree
Subjects Gender
Age of test
(years)
Age of onset
(years)
Systolic
pressure (mmHg)
Diastolic
pressure (mmHg)
IVST (mm)
(6–12mm)
LVMI
(g/m2)E C G C R ( mmol/l) UR (mmol/l)
I-2 F 65 65 165 110 — — — — —
II-2a F6 3 6 0 1 6 5 1 1 0 —— — — —
II-3a M 70 65 170 95 9 123.77 SB 84 5.1
II-4a F 64 31 200 100 10 84.58 MI 64 6.3
II-6a F 56 46 150 96 9 77.45 N 58 5.5
II-8a F 53 53 150 100 8 85.71 MI 55 3.9
II-9a M 60 54 190 110 12 72.59 LVH 70 5.5
III-1a M 57 54 140 90 10 97.99 N 75 7.1
III-3 M 48 — 120 80 8 59.74 N 80 7.2
III-4 M 46 — 130 80 10 132.66 MI 66 5.8
III-5 F 51 51 140 95 9 89.69 MI 48 4.6
III-6 M 38 — 125 85 — — — — —
III-7 M 38 — 120 75 — — — — —
III-8 F 41 — 130 80 8 97.15 ST-E 63 5.9
III-9 F 30 — 115 85 — — — — —
III-10 F 33 — 125 80 — — — — —
III-11 M 26 — 135 75 — — — — —
Abbreviations: F, female, M, male; IVST, interventricular septal thickness; LVMI, left ventricular mass index; N, electrocardiography (ECG) was normal; LVH, ECG showed left ventricular hypertrophy;
MI, myocardial ischemia; SB, sinus bradycardia; ST-E, ST segment elevation; CR, creatinine; UR, urea nitrogen.
aThese patients had antihypertension treatment. This table shows pre-treatment blood pressures.
Table 2 Summary of laboratory examinations for some members of a
Chinese family
Subjects II-4 II-6 II-8 II-9 Chinese reference
Therapy Yes Yes Yes Yes —
Alcohol No No No Yes —
Tobacco No No No Yes —
FPG, mmol/l 5.6 4.4 4.6 4.8 3.90–6.10
TC, mmol/l 5.22 4.3 5.68 3.8 2.44–5.17
TG, mmol/l 1.92 1.76 1.13 1.1 0.40–1.70
HDL, mmol/l 1.34 1.91 1.74 1.13 1.16–1.42
LDL, mmol/l 3.04 1.45 2.97 2.2 2.10–3.10
UA, mmol/l 415 268 226 358 214–488 (137–363)a
Abbreviations: FPG, fasting blood glucose; TC, total cholesterol; TG, triglyceride; HDL,
high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; UA, uric acid.
aReference value especially for females.
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adenine at this position is an extraordinarily conserved base in every
sequenced methionine tRNA from bacteria to human mitochon-
dria.32,33 The nucleotide at the position 37 is more prone to modiﬁca-
tion than those at other places of tRNA.34 The nucleotide modiﬁcation
at this position has been shown to have a pivotal role in the
stabilization of tertiary structure and the biochemical function of
tRNA.34 To determine if the 4435A4G mutation is present in
homoplasmy, the fragments spanning the tRNAMet gene were PCR-
ampliﬁed and subsequently digested with NlaIII. There was no
detectable wild-type DNA in all available matrilineal relatives (data
not shown), indicating that the 4435A4G mutation was present in
homoplasmy in these matrilineal relatives.
DISCUSSION
In the present study, we have performed the clinical, genetic and
molecular characterization of a Han Chinese family with essential
hypertension. The hypertension as a sole clinical phenotype was only
present in all matrilineal relatives of this three-generation pedigree.
Clinical and genetic evaluation revealed the variable severity and age at
onset in hypertension. In particular, the age at onset of hypertension
i nt h ea f f e c t e dm a t r i l i n e a lr e l a t i v e si nt h i sf a m i l yv a r i e df r o m3 1t o6 5
years, with an average of 52 years. This result was comparable to those
of other Chinese families with maternally transmitted hyperten-
sion.14,15,16,17 Mutational analysis of mitochondrial genome in this
family identiﬁed the tRNAMet 4435A4G mutation and other 35
variants belonging to the Eastern–Asian haplogroup G2a1.20 On the
other hand, the 4435A4G mutation also occurred in the other
mtDNA haplogroups B5a, D, M7a2 and J.17–19,35 This suggested
that the 4435A4G mutation occurred sporadically and multiplied
through evolution of the mtDNA. The 4435A4Gm u t a t i o nw a s
associated with essential hypertension in a Chinese family,17 and
other clinical abnormalities including Leber’s hereditary optic neuro-
pathy18 and type 2 diabetes.19 The occurrence of the 4435A4G
mutation in these genetically unrelated subjects affected by the
hypertension suggests that this mutation is involved in the pathogen-
esis of hypertension.
It was anticipated that the 4435A4G mutation resulted in a
deﬁcient nucleotide modiﬁcation at position 37 of tRNAMet,t h e r e b y
altering the structure and function of tRNAMet. Functional signiﬁcance
of the 4435A4G mutation was supported by the fact that B40–50%
reduction in the levels of tRNAMet was observed in cells carrying the
4435A4G mutation.17,18 As a result, a failure in the tRNAMet
metabolism is responsible for the reduced rate of mitochondrial
protein synthesis. Subsequently, these defects led to an impairment
of the mitochondrial respiration chain function, reduction of ATP
production and increase of reactive oxygen species production. These
mitochondrial dysfunctions may contribute to the development of
hypertension.7,10,15,36–38 In particular, the impaired mitochondrial
function could contribute to the characteristic age-related increase
in blood pressure.39 The homoplasmic form, mild mitochondrial
dysfunction, late onset and incomplete penetrance of hypertension
observed in this Chinese family carrying the 4435A4Gm u t a t i o n
suggest that the mutation is an inherited risk factor necessary for the
development of hypertension but may by itself be insufﬁcient to
produce a clinical phenotype. Indeed, the incomplete penetrance of
other clinical abnormalities arises from homoplasmic mtDNA muta-
tions such as hypertension-associated mtDNA 4401A4G mutation,15
deafness-associated 12S rRNA 1555A4Gm u t a t i o n 40 and Leber’s
hereditary optic neuropathy-associated ND4 11778G4A mutation.41
These homoplasmic mtDNA mutations only exhibited mild mito-
chondrial dysfunction.15,16,40,42 The other modiﬁer factors such as
nuclear modiﬁer genes, environmental and epigenetic factors, and
personal lifestyles39,43 may contribute to the development of hyperten-
sion in these subjects carrying the 4435A4G mutation. In particular,
the tissue speciﬁcity of this mutation is likely attributed to tissue-
speciﬁc RNA modiﬁcation or the involvement of nuclear modiﬁer
genes. The 4435A4G mutation should be added to the list of
inherited risk factors for future molecular diagnosis. Those who are
positive for the 4435A4Gm u t a t i o ns h o u l db ew a r n e dt h a tt h e ya r ea t
risk for the development of hypertension and therefore pay attention
to their personal lifestyles. In conclusion, our data support the
Table 3 mtDNA variants in one Han Chinese subject (II-6) with
hypertension
Gene Position Replacement
Conservation
H/M/B/Xa
Previously
reportedb
D-Loop 73 A to G Yes
152 T to C Yes
263 A to G Yes
310 T to CTC Yes
489 T to C Yes
16223 C to T Yes
16227 A to G Yes
16272 A to G Yes
16278 C to T Yes
16319 G to A Yes
16362 T to C Yes
16519 T to C Yes
12S rRNA 709 G to A G/A/A/A Yes
750 A to G A/G/A/A Yes
1438 A to G A/A/A/G Yes
16S rRNA 2706 A to G A/A/G/A Yes
tRNAMet 4435 A to G A/A/A/A Yes
ND2 4769 A to G Yes
4833 A to G (Thr to Ala) T/I/I/L Yes
5108 T to C Yes
tRNAAla 5601 C to T C/C/C/G Yes
CO1 7028 C to T Yes
CO2 7600 G to A Yes
ATP6 8701 A to G (Thr to Ala) T/S/L/Q Yes
8860 A to G (Thr to Ala) T/A/A/T Yes
CO3 9377 A to G Yes
9540 T to C Yes
9575 G to A Yes
ND3 10398 A to G (Thr to Ala) T/T/T/A Yes
10400 C to T Yes
ND4 10873 T to C Yes
11719 G to A Yes
tRNALeu(CUN) 12280 A to G A/G/A/A Yes
ND5 12705 C to T Yes
13563 A to G Yes
14034 T to C Yes
ND6 14569 G to A Yes
CYB 14766 C to T (Thr to Ile) T/S/T/S Yes
14783 T to C Yes
15043 G to A Yes
15301 G to A Yes
15326 A to G (Thr to Ala) T/M/I/I Yes
aConcervation of amino acid for polypeptides or nucleotide for rRNAs, in human (H), mouse
(M), bovine (B), and Xenopus laevis (X).
bSee http//www.mitomap.org and http://www.genpat.uu.se/mtDB/.
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the 4435A4Gt R N A Met mutation was associated with essential hyper-
tension. Therefore, our ﬁndings will be helpful for counseling families
of maternally inherited hypertension.
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